TherapeuticsMD Announces Third Quarter 2026 Financial Results
TherapeuticsMD, Inc. (TXMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE TherapeuticsMD Announces Third Quarter 2026 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)—November 13, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties,
How this was made
The 30-second read
Why it matters
The Q3 earnings release provides the first public data on the company's post‑transition performance, offering a new pricing reference for the stock.
Market read
First‑time earnings data for a micro‑cap royalty firm; may drive short‑term price movement.
What to watch
Potential litigation with Mayne Pharma and reliance on a single license partner could limit upside.
Background
TherapeuticsMD transitioned from women's health products to a royalty‑focused model in 2022 and now reports quarterly royalty income.
Ticker impact
TherapeuticsMD reported Q3 2026 results with net income of $0.5M and license revenue of $1.3M, a 60% YoY increase.
likely modest upside as higher license revenue beats expectations
The surprise increase in license revenue and profitability provides a fresh catalyst for a thinly‑traded stock.
Market effects
May signal stronger royalty‑based revenue trends for niche pharma royalty companies.
Limited to US small‑cap market; no broader regional effect.
Minimal global impact beyond sector niche.
Counterpoint
Investors may view the modest profit as insufficient and sell on valuation concerns.
Key entities
- CompanyTherapeuticsMD, Inc.
NASDAQ‑listed pharmaceutical royalty company.
- LicenseeKnight
Partner that triggered a $365k milestone payment.
